Pharma Marketing News Vol. 12, No. 7: 9 September 2013

Welcome to Volume 12, Issue #7 (9 September 2013) of Pharma Marketing News.

Pharma Marketing News Vol. 12, No. 5: 20 May 2013

Welcome to Volume 12, Issue #5 (20 May 2013) of Pharma Marketing News.

The Comeback of CME without Pharma: More Physician Participants, More Revenue, But Less Pharma...

Although the pharmaceutical industry still contributes slightly over $1 billion to support healthcare professional continuing medical education (CME) via grants, advertising, and exhibits, total pharma support continues to decrease.

Pharma Marketing News Vol. 12, No. 8: October 2013

Welcome to Volume 12, Issue #8 (October 2013) of Pharma Marketing News.

Help Doctors Educate Patients About Their Condition & Treatment

Vivacare offers industry partners (pharmaceutical firms, device firms and/or their agencies) an opportunity to develop and distribute 'Disease Education Kits' that leverage Vivacare's patient education platform and physician network. This article is a review of Vivacare's service as part of a pharmaceutical brand's digital marketing efforts.

Pharma and Social Media – Comfy Bedfellows: Boehringer, AstraZeneca, & Janssen Get It On!

This article reviews social media breakthroughs by Boehringer, AstraZeneca, & Janssen.

Self-Regulation as a Collective Blocking Strategy

Has the drug industry systematically violated PhRMA's DTC Principles? Is pharma self-regulation a deception meant to deflect criticism and block new FDA regulations? The answer is

Toward Patient-Centric Marketing: Working Effectively with Patient Groups

Putting in place a patient-centric marketing approach might prove a good strategy for a pharma company. Patient groups and patients are invited to the table to debate regulatory issues, political policy issues and in some cases reimbursement issues as well. This article summarizes two presentations made at the eyeforpharma Barcelona 2013 conference.

Pharma Marketing News Vol. 12, No. 6: 31 July 2013

Welcome to Volume 12, Issue #6 (31 June 2013) of Pharma Marketing News.

Bad, Devalued, Distrusted & Defensive Pharma

This article, however, tells the Tale of Two Books: Bad Pharma, a 430-page book by Ben Goldacre, a British physician, whose previous book, Bad Science, was a best seller in the 'non-fiction' realm and the much smaller 123-page book Devalued and Distrusted by John L. LaMattina, former president of research and develop at Pfizer.
- Advertisement -